ASCO 2022 | Sabizabulin in men with mCRPC who progressed on an androgen receptor targeting agent

Mark Christopher Markowski, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, discusses the final analysis of the Phase Ib/II study of sabizabulin, a novel oral cytoskeleton disruptor, in men with metastatic castration-resistant prostate cancer (mCRPC) who progressed on an androgen receptor targeting agent. This clinical trial demonstrated that chronic oral daily dosing of sabizabulin has a favorable safety profile with significant preliminary cytotoxic and cytostatic antitumor activity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.